Management of moderate to severe psoriasis with systemic immunomodulatory therapies: a 5‐year experience from two departments of dermatology of Northern France

Staumont‐Sallé, D.; Florin, V.; Cottencin, A.-C.; Chaby, G.; Delaporte, E.

doi:10.1111/j.1468-3083.2011.04180.x

Cited by 2 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with psoriasis taking MTX had a higher risk of NMSC development than those not taking MTX (estimated odds ratio (OR) = 2.8; 95% CI = 1.47-5.39; p = 0.002); heterogeneity was moderate, as stated (I 2 = 42.6%; p = 0.08) (Figure 2) [27][28][29][30][31][32][33][34][35]. Odds of developing NMSC in patients with psoriasis treated with MTX compared to patients with psoriasis not treated with MTX; black horizontal lines, 95% CIs for individual studies; black vertical line, lack of statistical significance; red vertical line, the overall OR for all studies; blue diamond, the overall effect for all studies.…”

Section: Data Synthesismentioning

confidence: 94%

“…Of these articles, 176 were excluded. This resulted in nine articles that met the inclusion criteria (Table 1) [27][28][29][30][31][32][33][34][35]. Of the 185 studies included for a full review, there were no disagreements regarding final study inclusion between the independent evaluators.…”

Section: Studies Includedmentioning

confidence: 99%

“…Thus, ultimately, there was agreement in the overall categorical rating of each article. As agreed upon by both evaluators, all studies were deemed high quality and demonstrated a low risk of bias based on the Newcastle-Ottawa Scale (Tables 2, 3) [27][28][29][30][31][32][33][34][35]. Mali-Gerrits et al…”

Section: Risk Of Biasmentioning

confidence: 99%

See 2 more Smart Citations

Psoriasis Patients Treated With Methotrexate Have an Increased Risk of Nonmelanoma Skin Cancer: A Systematic Review and Meta-Analysis

Houser¹,

Stewart²,

Brewer³

2023

Cureus

View full text Add to dashboard Cite

Both psoriasis and methotrexate are associated with an increased risk of nonmelanoma skin cancer. The effect of methotrexate on the development of nonmelanoma skin cancer in patients with psoriasis is currently unknown. To evaluate this relationship, a systematic review of the literature was conducted using databases including Ovid Medline (from 1946), Scopus (from 1970), and Embase (from 1974) through June 2019. Observational comparative and case-control studies comparing psoriasis patients treated with methotrexate to those not treated with methotrexate with data on the subsequent development of nonmelanoma skin cancer in both cohorts were included based on prespecified criteria. Two reviewers analyzed all studies for relevant data, which were analyzed using OpenMeta-Analyst statistical software. Quality was assessed with the Newcastle-Ottawa method. Nine cohort and case-control comparative studies of 1,486 screened abstracts met the inclusion criteria. Of 11,875 reported patients with psoriasis, 2,192 were taking methotrexate. A meta-analysis demonstrated an odds ratio of 2.8 (95% confidence interval = 1.47-5.39; p = 0.002) for nonmelanoma skin cancer development in patients with psoriasis taking methotrexate compared with those not taking methotrexate. Based on these findings, psoriasis patients treated with methotrexate are at a significantly increased (2.8 times higher) risk of developing nonmelanoma skin cancer. Risk counseling can improve healthcare outcomes in patients with psoriasis.

show abstract